Novacept NovaSure To Compete With Ethicon In U.S. Menorrhagia Market
This article was originally published in The Gray Sheet
Executive Summary
The relatively short procedure time required for endometrial ablation with Novacept's NovaSure device will prove a key advantage over other menorrhagia treatment systems, the firm maintains.
You may also be interested in...
Cytyc Expands Women’s Health Niche With Novacept Menorrhagia Treatment
Cytyc will double its sales force targeting ob/gyn physicians to 200 reps following its acquisition of Novacept, in an effort to make NovaSure the top-selling menorrhagia treatment system
Cytyc Expands Women’s Health Niche With Novacept Menorrhagia Treatment
Cytyc will double its sales force targeting ob/gyn physicians to 200 reps following its acquisition of Novacept, in an effort to make NovaSure the top-selling menorrhagia treatment system
CDRH Turns In Strong Performance For Premarket Reviews In Fiscal Year 2001
FDA's Office of Device Evaluation maintained 510(k) total review times near statutory timelines in fiscal year 2001, despite the increasing strain on center resources.